Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 0.48 |
| ▸ | DHFR | P00374 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4526172 | 0.89 | PTPN1 (0.59) | PTPN1DHFRMAP4K4HRH4SRC | |
| Trifluoroacetic Acid SCHEMBL4510501 | 0.89 | PTPN1 (0.51) | PTPN1DHFRMAP4K4SRCCYP1A2 | |
| Trifluoroacetic Acid SCHEMBL4533714 | 0.88 | PTPN1 (0.49) | PTPN1DHFRCYP1A2CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4524510 | 0.87 | PTPN1 (0.50) | PTPN1DHFRCYP1A2CYP2D6CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL4528055 | 0.87 | MAP4K4 (0.43) | PTPN1DHFRMAP4K4 | |
| Trifluoroacetic Acid SCHEMBL4528549 | 0.86 | DHFR (0.50) | PTPN1DHFRMAP4K4HRH4CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL4525618 | 0.85 | DHFR (0.52) | PTPN1DHFRMAP4K4HRH4CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL4519544 | 0.85 | APP (0.40) | DHFRJAK2TYK2FABP4 | |
| Trifluoroacetic Acid SCHEMBL5499368 | 0.84 | PTPN1 (0.39) | PTPN1DHFRCYP1A2CYP3A4CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL4533732 | 0.83 | PTPN1 (0.52) | PTPN1MAP4K4HRH4CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812409-A1 | AMINOQUINAZOLINES COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | claimed |
| WO-2006050843-A1 | AMINOQUINAZOLINES COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | claimed |
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
| EP-1812409-A1 | AMINOQUINAZOLINES COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | disclosed |
| WO-2006050843-A1 | AMINOQUINAZOLINES COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | PTPN1 2/4885DHFR 2071/4885MAP4K4 639/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | PTPN1 2/4885DHFR 2071/4885MAP4K4 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.